Plain-English translation of NCT04186520 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new type of immunotherapy called CAR-20/19-T cells for people with blood cancers (like lymphoma and leukemia) that have stopped responding to standard treatments. These cells are created in a lab by taking some of your own immune cells, engineering them to recognize and attack cancer cells, and then giving them back to you as an infusion. The study is checking whether this treatment is safe and how well it works.
When blood cancers come back after initial treatment or don't respond to standard therapies, options become very limited and the outlook is often poor. This medication represents a new approach—using your own immune system as a weapon against cancer—and researchers want to understand if it can help patients in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You will first have blood drawn and imaging tests (like MRI or CT scans) to confirm your cancer and check your organ function. If you qualify, your own immune cells will be collected through a procedure called apheresis (similar to donating plasma). These cells are then sent to a lab where they are engineered over 8 to 12 days. Once ready, you will receive the modified cells back as an infusion in the hospital, where you'll be monitored closely for side effects. You'll have follow-up visits to track how you respond and how you feel over the coming weeks and months.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States